Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRV002
MIFTS: 44

Cervix Uteri Carcinoma in Situ

Categories: Cancer diseases, Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Cervix Uteri Carcinoma in Situ

About this section

MalaCards integrated aliases for Cervix Uteri Carcinoma in Situ:

Name: Cervix Uteri Carcinoma in Situ 12 15
Carcinoma in Situ of Uterine Cervix 12 71
Cervical Intraepithelial Neoplasia 43 71
Cervical Intraepithelial Neoplasia Grade Iii with Severe Dysplasia 12
Cervix Intraepithelial Neoplasia Grade 3 Ajcc V7 71
Squamous Intraepithelial Neoplasia, Grade Iii 12
Cin Iii - Carcinoma in Situ of Cervix 12
Severe Dysplasia of the Cervix Uteri 12
Cin Iii - Severe Dyskaryosis 12
Carcinoma in Situ of Cervix 12
Carcinoma of Cervix Stage 0 12
Severe Dysplasia of Cervix 12
Cervix Ca in Situ 12
Cin Iii 12

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:8991
ICD9CM 34 233.1
MeSH 43 D018290
NCIt 49 C4000
ICD10 32 D06 D06.9
UMLS 71 C0206708 C0851140 C2987516
Sources

Summaries for Cervix Uteri Carcinoma in Situ

About this section
Disease Ontology : 12 An in situ carcinoma that is located in the uterine cervix.

MalaCards based summary : Cervix Uteri Carcinoma in Situ, also known as carcinoma in situ of uterine cervix, is related to cervicitis and cervical intraepithelial neoplasia. An important gene associated with Cervix Uteri Carcinoma in Situ is MIR548B (MicroRNA 548b), and among its related pathways/superpathways is Platelet Adhesion to exposed collagen. The drugs Aluminum hydroxide and Pravastatin have been mentioned in the context of this disorder. Affiliated tissues include uterine cervix, cervix and testes.

Sources

Related Diseases for Cervix Uteri Carcinoma in Situ

About this section

Diseases in the Rare Cancer of Cervix Uteri family:

Cervix Uteri Carcinoma in Situ

Diseases related to Cervix Uteri Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 188)
# Related Disease Score Top Affiliating Genes
1 cervicitis 31.5 SERPIND1 GP6 GP5 CDKN2A
2 cervical intraepithelial neoplasia 31.2 KRT17 FHIT CDKN2A
3 in situ carcinoma 31.0 TP53 MIR654 MIR548B KRT17 CDKN2A
4 vulvar intraepithelial neoplasia 30.6 TP53 CDKN2A
5 cervical carcinosarcoma 30.6 MAPK8IP1 GP5
6 vaginal disease 30.6 TP53 LINC01191 GP5
7 cervical adenocarcinoma 30.5 TP53 PAX1 CDKN2A
8 suppressor of tumorigenicity 3 30.5 TP53 FHIT CDKN2A
9 cervical squamous cell carcinoma 30.5 TP53 KRT17 CDKN2A
10 cervix carcinoma 30.4 TP53 MAPK8IP1 INSM1 FHIT CDKN2A
11 epidermodysplasia verruciformis 1 30.4 TP53 GP6 GP5
12 keratinizing squamous cell carcinoma 30.4 TP53 LINC01191 CDKN2A
13 anus cancer 30.4 TP53 LINC01191 GP6 GP5 CDKN2A
14 ovarian squamous cell carcinoma 30.3 LINC01191 CDKN2A
15 endocervical adenocarcinoma 30.3 TP53 MAPK8IP1 CDKN2A
16 vaginal cancer 30.2 TP53 MAPK8IP1 LINC01191 INSM1 GP5 CDKN2A
17 oropharynx cancer 30.2 TP53 GP6 GP5 CDKN2A
18 vulva cancer 30.1 TP53 LINC01191 GP5 CDKN2A
19 cervical incompetence 30.1 PTPRN MAPK8IP1 INSM1
20 chronic cervicitis 30.0 TP53 SERPIND1 KRT17 KLHL40 GP6 GP5
21 anogenital venereal wart 29.9 TP53 LINC01191 GP6 GP5 CDKN2A
22 cervical cancer 29.6 TP53 RUBCNL PAX1 MIR338 KRT17 FHIT
23 cervix disease 29.2 TP53 PTPRN MIR338 MAPK8IP1 INSM1 GP5
24 chlamydia 10.7
25 immune deficiency disease 10.6
26 bacterial vaginosis 10.5
27 vaginal discharge 10.5
28 early invasive cervical adenocarcinoma 10.5 INSM1 CDKN2A
29 cervical adenosarcoma 10.5 GP6 GP5
30 retinoblastoma 10.5
31 familial retinoblastoma 10.5
32 ovarian seromucinous carcinoma 10.4 TP53 CDKN2A
33 esophagus verrucous carcinoma 10.4 TP53 CDKN2A
34 spitz nevus 10.4 TP53 CDKN2A
35 focal epithelial hyperplasia 10.4 GP6 GP5
36 comedo carcinoma 10.4 TP53 GP5
37 cervical clear cell adenocarcinoma 10.4 MAPK8IP1 GP5
38 basosquamous carcinoma 10.4 TP53 KRT17
39 cervical adenoid basal carcinoma 10.4 MAPK8IP1 KRT17
40 oral leukoplakia 10.4 TP53 CDKN2A
41 hemometra 10.4 MAPK8IP1 INSM1
42 soft palate cancer 10.4 GP6 CDKN2A
43 thyroid lymphoma 10.4 TP53 CDKN2A
44 vaginitis 10.4
45 herpes simplex 10.4
46 eccrine acrospiroma 10.4 TP53 KRT17
47 pharynx cancer 10.4 TP53 MIR338 CDKN2A
48 dedifferentiated liposarcoma 10.4 TP53 CDKN2A
49 large cell acanthoma 10.4 TP53 KRT17
50 adult malignant schwannoma 10.3 TP53 CDKN2A

Comorbidity relations with Cervix Uteri Carcinoma in Situ via Phenotypic Disease Network (PDN):


Myofibroma

Graphical network of the top 20 diseases related to Cervix Uteri Carcinoma in Situ:



Diseases related to Cervix Uteri Carcinoma in Situ
Sources

Symptoms & Phenotypes for Cervix Uteri Carcinoma in Situ

About this section
Sources

Drugs & Therapeutics for Cervix Uteri Carcinoma in Situ

About this section

Drugs for Cervix Uteri Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
2
Pravastatin Approved Phase 4 81093-37-0 54687
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
6 Monophosphoryl lipid A Phase 4
7 Hypolipidemic Agents Phase 4
8 Anticholesteremic Agents Phase 4
9 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
10 Lipid Regulating Agents Phase 4
11 Central Nervous System Depressants Phase 4
12 Anesthetics, Local Phase 4
13 Epinephryl borate Phase 4
14 Neurotransmitter Agents Phase 4
15 Sympathomimetics Phase 4
16 Anti-Asthmatic Agents Phase 4
17 Vasoconstrictor Agents Phase 4
18 Adrenergic Agonists Phase 4
19 Adrenergic beta-Agonists Phase 4
20 Respiratory System Agents Phase 4
21 Autonomic Agents Phase 4
22 Mydriatics Phase 4
23 Bronchodilator Agents Phase 4
24 Adrenergic Agents Phase 4
25
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
26
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
27
Bevacizumab Approved, Investigational Phase 3 216974-75-3
28
Pancrelipase Approved, Investigational Phase 3 53608-75-6
29
Eugenol Approved Phase 3 97-53-0 3314
30
leucovorin Approved Phase 3 58-05-9 6006 143
31
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
32
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
33
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
34
Aluminum sulfate Approved Phase 3 10043-01-3
35
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
36
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
37
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
38
Fenretinide Investigational Phase 3 65646-68-6
39
3,3'-diindolylmethane Investigational Phase 3 1968-05-4
40 Vitamin B Complex Phase 3
41 Vitamin B9 Phase 3
42 Folate Phase 3
43 Micronutrients Phase 3
44 Vitamins Phase 3
45 Trace Elements Phase 3
46 Hematinics Phase 3
47 Nutrients Phase 3
48 Retinamide Phase 3
49 Dermatologic Agents Phase 3
50 Antiviral Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 306)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer Unknown status NCT02629510 Phase 4 Tachosil
2 Can Mindfulness Meditation Limit the Progression and/or Increase the Remission of Cervical Dysplasia? Unknown status NCT00842738 Phase 4
3 HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico Unknown status NCT03105856 Phase 4
4 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
5 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
6 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
7 Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization During General Anesthesia: A Randomized Controlled Double Blinded Study Completed NCT02368054 Phase 4 Bupivacaine;Adrenaline
8 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
9 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
10 Quadrivalent HPV Vaccination After Effective Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Completed NCT02087384 Phase 4 Placebo
11 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study Recruiting NCT03180034 Phase 4
12 Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study Active, not recruiting NCT03629886 Phase 4
13 Effectiveness of Cervical Screening in HPV Vaccinated Women - A Randomized Trial Enrolling by invitation NCT02149030 Phase 4
14 Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation Unknown status NCT01095198 Phase 2, Phase 3
15 The Study of Folate Receptor-Mediated Staining Solution (FRDâ„¢) In Cervical Unknown status NCT03366493 Phase 3
16 A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3 Completed NCT00003075 Phase 3 Fenretinide
17 Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1 Completed NCT00156026 Phase 3
18 Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
19 Long-term Extension Study of the Efficacy of the 580299 Vaccine in the Prevention of HPV-16 and/or HPV-18 Associated Cervical Intraepithelial Neoplasia (CIN) in Japanese Women Vaccinated in the Primary Vaccination Study NCT00316693 Completed NCT00929526 Phase 3
20 Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects From the HPV-058 Study Completed NCT03355820 Phase 3
21 A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica. Completed NCT00128661 Phase 3
22 Diindolylmethane (DIM) Dietary Supplementation: A Nonsurgical Treatment for Cervical Intraepithelial Neoplasia (CIN) Completed NCT00212381 Phase 3 di indolylmethane (DIM)
23 An Investigation Into the Effects of Diidolylmethane (BioResponse DIM®) Supplementation in Women With Low-Grade Cervical Cytological Abnormalities [CRISP-1] Completed NCT00462813 Phase 3 oral microencapsulated diindolylmethane
24 Lidocaine Spray Compared With Submucosal Injection in Reducing Pain During Loop Electrosurgical Excision Procedure: a Randomized Controlled Trial Completed NCT01505920 Phase 3
25 A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women Completed NCT00000758 Phase 3 Fluorouracil
26 Single Visit Cervical Cancer Prevention Program Completed NCT00237562 Phase 3
27 A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013 Completed NCT00316706 Phase 3
28 Large Loop Excision of Transformation Zone Cone Versus Straight Wire Excision of Transformation Zone : Histopathological Analysis of Excision Margins Completed NCT01929993 Phase 3
29 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
30 Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT02562508 Phase 3
31 Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial Completed NCT02330471 Phase 3
32 A Study of Two Cone Biopsy Techniques For Women With Cervical Pre-Invasive Disease. LLETZ Cone and SWETZ. Completed NCT00995020 Phase 3
33 A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix Completed NCT00264732 Phase 2, Phase 3 Amolimogene;Amolimogene
34 A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women Completed NCT00834106 Phase 3
35 Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
36 A Randomized Phase III Trial of Oral Isotretinoin Versus Observation for Low-Grade Squamous Intraepithelial Lesions in HIV-Infected Women Completed NCT00001073 Phase 3 Isotretinoin
37 A Long-term, Open, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 Vaccine in Healthy Female Subjects Vaccinated Either Pre- or Post-menarche in the Primary Study Completed NCT00337818 Phase 3
38 Clinical Evaluation of the APTIMA® HPV Assay on the TIGRIS® DTS® System in Women With ASC-US Pap Test Results and in Women 30 Years of Age or Older With Negative Pap Test Results Using ThinPrep Pap Test Specimens Completed NCT00973362 Phase 3
39 A Phase III, Randomized, Two-armed, Double-blind (Patient and Assessors), Parallel Active Controlled Non-Inferiority Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab (Produced by AryoGen Pharmed) Plus FOLFIRI-3 Compared With Bevacizumab (Avastin®) Plus FOLFIRI-3 in Patients With Metastatic Colorectal Cancer (mCRC) Completed NCT03288987 Phase 3 Bevacizumab + FOLFIRI-3
40 Human Papillomavirus DNA Testing Using Self-collected Samples for Cervical Cancer Screening: an Alternative Strategy for Unscreened Women? Completed NCT01014026 Phase 3
41 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Completed NCT01131312 Phase 3
42 Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients. Completed NCT00677677 Phase 3
43 Efficiency of AV2 Antiviral Drug in the Treatment of Human Papillomavirus-associated Precancerous Lesions of the Uterine Cervix: a Randomized Clinical Trial in Kinshasa, Democratic Republic of the Congo Completed NCT02346227 Phase 3 AV2;Placebo
44 Randomized Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL Recruiting NCT03721978 Phase 3
45 A Phase III, Randomized, Two Armed, Parallel, Double-blind, Active-controlled, Equivalency Clinical Trial to Determine the Therapeutic Efficacy and Safety Between Cetuximab® (Produced by CinnaGen) and FOLFIRI Compared With Erbitux® (Cetuximab, the Reference Drug, Produced by Merck Company) and FOLFIRI for RAS Wild-type Metastatic Colorectal Cancer Patients Recruiting NCT03391934 Phase 3 Cetuximab + FOLFIRI
46 A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL® Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of Age Recruiting NCT03998254 Phase 3 V503;Gardasil
47 A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment Recruiting NCT02669459 Phase 3 Imiquimod
48 A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRAâ„¢-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix Active, not recruiting NCT03185013 Phase 3
49 A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women Active, not recruiting NCT01735006 Phase 3
50 A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years Active, not recruiting NCT03493542 Phase 3

Search NIH Clinical Center for Cervix Uteri Carcinoma in Situ

Cochrane evidence based reviews: cervical intraepithelial neoplasia

Sources

Genetic Tests for Cervix Uteri Carcinoma in Situ

About this section
Sources

Anatomical Context for Cervix Uteri Carcinoma in Situ

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Cervix Uteri Carcinoma in Situ:

19
Uterine Cervix

MalaCards organs/tissues related to Cervix Uteri Carcinoma in Situ:

40
Cervix, Testes, T Cells, Breast, Endothelial, Skin, Lymph Node
Sources

Publications for Cervix Uteri Carcinoma in Situ

About this section

Articles related to Cervix Uteri Carcinoma in Situ:

(show top 50) (show all 7622)
# Title Authors PMID Year
1
Disease detection at the 48-month exit round of the HPV FOCAL cervical cancer screening trial in women per-protocol eligible for routine screening. 61
31245842 2020
2
The prevalence of VAIN, CIN, and related HPV genotypes in Japanese women with abnormal cytology. 61
31642536 2020
3
Does the trend toward less deep excisions in LLETZ to minimize obstetric risk lead to less favorable oncological outcomes? 61
31814122 2020
4
Genetic variability and functional implication of HPV16 from cervical intraepithelial neoplasia in Shanghai women. 61
31670402 2020
5
Incomplete excision of cervical intraepithelial neoplasia as a predictor of the risk of recurrent disease-a 16-year follow-up study. 61
31473226 2020
6
Tissue-based metabolomics reveals potential biomarkers for cervical carcinoma and HPV infection. 61
31465717 2020
7
Will HPV vaccination prevent cervical cancer? 61
31962050 2020
8
HPV infection screening using surface plasmon resonance in women from Kunming (Southwest China). 61
31509732 2020
9
Identification of HPV Genotypes Causing Cervical Pre-Cancer using Tissue-Based Genotyping. 61
32037535 2020
10
Evaluation of multiple screening methods for cervical cancers in rural areas of Xinjiang, China. 61
32028440 2020
11
Long-term predictors of residual or recurrent cervical intraepithelial neoplasia 2-3 after treatment with a large loop excision of the transformation zone: a retrospective study. 61
31631477 2020
12
Doctor and patient awareness of treatment options for cervical intraepithelial neoplasia 1 (CIN 1): a survey questionnaire approach. 61
31475593 2020
13
Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study. 61
30892587 2020
14
HLA-B*38:165N and HLA-B*51:309 alleles identified in two Chinese cervical intraepithelial neoplasia patients. 61
32026562 2020
15
Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women. 61
31871224 2020
16
Triage of low-grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests-A prospective population-based register study. 61
31562779 2020
17
Incidental Serous Tubal Intraepithelial Carcinoma that Developed into Primary Peritoneal Serous Carcinoma in a Patient without BRCA Mutation. 61
32034117 2020
18
Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015. 61
30980692 2020
19
Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting. 61
30861114 2020
20
Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature. 61
31959338 2020
21
Clinical evaluation of modifications to a human papillomavirus assay to optimise its utility for cervical cancer screening in low-resource settings: a diagnostic accuracy study. 61
31981559 2020
22
Peripheral blood circulating microRNA-4636/-143 for the prognosis of cervical cancer. 61
31407404 2020
23
SIRT3 promotes the invasion and metastasis of cervical cancer cells by regulating fatty acid synthase. 61
31677030 2020
24
Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review. 61
31714325 2020
25
Human papillomavirus Posttreatment Clearance Time in Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer. 61
31725049 2020
26
miR‑218 functions as a tumor suppressor gene in cervical cancer. 61
31746391 2020
27
HPV-mediated down-regulation of NOD1 inhibits apoptosis in cervical cancer. 61
32021648 2020
28
Assessing sociodemographic differences in human papillomavirus vaccine impact studies in the United States: a systematic review using narrative synthesis. 61
31698136 2020
29
Primary HPV testing with cytology versus cytology alone in cervical screening-A prospective randomized controlled trial with two rounds of screening in a Chinese population. 61
31922265 2020
30
Multistate Markov Model to Predict the Prognosis of High-Risk Human Papillomavirus-Related Cervical Lesions. 61
31979115 2020
31
Clinical performance of the HPV DNA Array genotyping assay in detection of CIN2+ lesions with BS GP5+/6+ MPG Luminex tested cervical samples. 61
31471920 2020
32
Evaluation of the intraoperative human papillomavirus test as a marker of early cure at 12 months after electrosurgical excision procedure in women with cervical high-grade squamous intraepithelial lesion: a prospective cohort study. 61
31502397 2020
33
Longitudinal assessment of abnormal Papanicolaou test rates among women with HIV. 61
31789890 2020
34
Genome-wide DNA methylation profiling identifies two novel genes in cervical neoplasia. 61
31983058 2020
35
TEST ACCURACY OF HUMAN PAPILLOMAVIRUS IN URINE FOR DETECTION OF CERVICAL INTRA-EPITHELIAL NEOPLASIA. 61
31896666 2020
36
LLETZ make it simple: Anxiety, pain and treatment outcomes with outpatient large loop excision of the transformation zone under local anaesthesia. 61
32002985 2020
37
Triaging women with human papillomavirus infection and normal cytology or low-grade dyskaryosis: evidence from 10-year follow up of the ARTISTIC trial cohort. 61
31541495 2020
38
Risk prediction of cervical abnormalities: The value of sociodemographic and lifestyle factors in addition to HPV status. 61
31756350 2020
39
Comparative performance evaluation of different HPV tests and triaging strategies using self-samples and feasibility assessment of thermal ablation in 'colposcopy and treat' approach: A population-based study in rural China. 61
31970767 2020
40
Cervical neoplastic lesions in relation to CD4 T-lymphocyte counts and antiretroviral therapy among women with clinical stage 1 HIV in Yunnan, China. 61
31913555 2020
41
BAG3 expression correlates with the grade of dysplasia in squamous intraepithelial lesions of the uterine cervix. 61
31444794 2020
42
[The role of human papillomavirus 16 early genes E2 and E6 and heterogeneous nuclear ribonucleoprotein E2 in cervical carcinogenesis and their interaction effect]. 61
31914575 2020
43
The human papillomavirus vaccine as a treatment for human papillomavirus-related dysplastic and neoplastic conditions: A literature review. 61
31085272 2020
44
Vaginal Intraepithelial Neoplasia: A Retrospective Study of Treatment and Outcomes Among a Cohort of UK Women. 61
31860574 2020
45
Association between Vaginal Micro-environment Disorder and Cervical Intraepithelial Neoplasia in a Community Based Population in China. 61
31897224 2020
46
Improvement in RNA quantity and quality in cervico-vaginal cytology. 61
31959186 2020
47
Outcomes in women with biopsy-confirmed cervical intraepithelial neoplasia grade 1 or normal cervix and related cofactors: A 15-year population-based cohort study from China. 61
31937451 2020
48
Cervical Intraepithelial Neoplasia Rates in British Columbia Women: A Population-Level Data Linkage Evaluation of the School-Based HPV Immunization Program. 61
31504649 2020
49
Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California, United States. 61
31611099 2020
50
A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3). 61
32005582 2020
Sources

Variations for Cervix Uteri Carcinoma in Situ

About this section
Sources

Expression for Cervix Uteri Carcinoma in Situ

About this section
Search GEO for disease gene expression data for Cervix Uteri Carcinoma in Situ.
Sources

Pathways for Cervix Uteri Carcinoma in Situ

About this section

Pathways related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Platelet Adhesion to exposed collagen 65
9.74 GP6 GP5
Sources

GO Terms for Cervix Uteri Carcinoma in Situ

About this section

Biological processes related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replicative senescence GO:0090399 8.96 TP53 CDKN2A
2 hemostasis GO:0007599 8.8 SERPIND1 GP6 GP5
Sources

Sources for Cervix Uteri Carcinoma in Situ

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....